NMPA Approves Toripalimab in patients with recurrent or metastatic Nasopharyngeal Carcinoma

▴ NMPA Approves Toripalimab in patients with recurrent or metastatic Nasopharyngeal Carcinoma
Approval comes after Failure of at Least Two Lines of Prior Systemic Therapy

Junshi Biosciences, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy. This is the first approval of immune checkpoint blockade therapy in NPC in the world and the second approved indication for toripalimab in China. In December 2018, Toripalimab obtained a conditional approval from the NMPA for the second-line treatment of unresectable or metastatic melanoma.

In April 2020, the supplemental NDA for Toripalimab in patients with recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy was accepted by the NMPA and received priority review designation from the NMPA in July 2020. The supplemental NDA is based on the POLARIS-02 study (NCT02915432), which is a multi-center, open-label, Phase II pivotal registrational clinical study led by Professor Ruihua Xu from Sun Yat-sen University Cancer Center. The study enrolled a total of 190 patients with recurrent or metastatic NPC after failure of prior systemic therapy. The POLARIS-02 study is the world’s largest clinical study for any immune checkpoint inhibitor monotherapy for the treatment of recurrent or metastatic NPC. In January 2021, the results of the POLARIS-02 study were published online in the Journal of Clinical Oncology.

The results of the POLARIS-02 study showed that Toripalimab demonstrated durable anti-tumor activity and survival benefits regardless of PD-L1 expression status with a manageable safety profile. In 92 patients with recurrent/metastatic NPC after failure of at least two lines of prior systemic chemotherapy, the objective response rate (ORR) was 23.9%; the median duration of response (mDOR) 14.9 months; and the median overall survival (mOS) 15.1 months.

"The great variability in prevalence of NPC across the globe is evident, which leads to challenges in new drug research and development on a global scale. Despite this, unmet medical needs for NPC remain globally. Our data show that NPC is clearly responsive to immunotherapy. It is notable that toripalimab lacks the usual side effects of cytotoxic therapy and is generally well tolerated by patients, showing a great potential for further development in the treatment of NPC," said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences.

"As an innovation-driven pharma who follows the ‘In China, For Global’ strategy, we focus on tumor types that are 1) highly prevalent in China; 2) responsive to immunotherapy; and 3) where there is urgent unmet need for better and safer treatments. We sincerely appreciate the contributions made by investigators and patients of the POLARIS-02 study, empowering us to obtain this critical medical evidence to advance treatment options for so many. In addition, we have also developed a R & D program for treatment of NPC, regardless of extent of prior treatment, and look forward to providing better treatment options for patients with advanced nasopharyngeal carcinoma in China and beyond."

Tags : #Toripalimab #Nasopharyngeal #Carcinoma #NMPA #LatestPharmaNews

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

It is important to adopt a non-judgmental attitude towards any teenage girl seeking contraceptive advise suggests Dr. Teena Trivedi, Obstetrician and GynecologistApril 16, 2021
80% of the diseases are psychosomatic which means they have roots in the mind and this is where homeopathy steps in - It resolves physical ailments by finding the cause in the mind – Dr. Sanket Dhuri, Consultant Homeopath April 14, 2021
A futuristic Vision of a Healthcare Entrepreneur: Shyatto Raha, CEO, and Founder of MyHealthcareApril 12, 2021
Saher Mehdi, Founder and Chief Scientist at wellOwise talks about aspects making healthcare more equitable and reachableApril 10, 2021
Wide variety of therapies to address autism in children explained by Dr. Shilpa Jasubhai, Clinical PsychologistApril 09, 2021
Allopathic and Homeopathic medicines should not be taken together says Dr. Sunil Mehra, Homeopath ConsultantApril 08, 2021
The charm of homeopathic medicine is that it can be taken with conventional medicines – Dr. Shruthi Shridhar, Consulting Homeopath April 08, 2021
Dissociative Identity Disorder and associated concepts explained by Dr. Vinod Kumar, Psychiatrist and Head of Mpower - The Centre (Bangalore) April 07, 2021
Dissociative Identity Disorder explained by Dr. Shilpa Jasubhai, Clinical PsychologistApril 05, 2021
Sehat Ki Baat, Karishma Ke Saath- Episode 6 Healthy Diet For Boosting Metabolism Which Can Help Thyroid Patients April 03, 2021
Significant Pointers on Kidney Health by Dr. Santosh Waigankar, Consultant Urooncologist and Robotic Surgeon at Kokilaben Dhirubhai Ambani HospitalApril 01, 2021
Dr. Vaishal Kenia, Ophthalmologist Talks About the Different Possibilities Available for the Treatment of Glaucoma Depending Upon Their Type and SeverityMarch 30, 2021
No Definitive Role of Diet in Treatment of Lymphedema but Intake of Calories, Salt and Long Chain Fatty Acids should be controlled says Dr. Ramani CVMarch 30, 2021
Dr. Kiran Chandra Patro, Senior Nephrologist Talks About Dialysis as the Temporary Process and Not a Permanent Cure for the Patients of Renal DysfunctionMarch 30, 2021
Two out of three new chronic kidney disease patients are found to have diabetes or hypertension informs Dr. Sreeharsha HarinathaMarch 30, 2021
Glaucoma Treatment: Medications or Surgery? A valuable piece of advice from Dr. Pranay Kapdia, Chairman and Medical Director of Kapadia Eye CareMarch 25, 2021
Dr. Shraddha Satav, Consultant Ophthalmologist Recommends that Everybody After 40, Should Go for the Complete Eye Checkup at Regular IntervalMarch 25, 2021
Childhood Obesity is not a Disease but a Condition which can be very well ManagedMarch 19, 2021
World Sleep Day - 19 th March 2021- Know More About Healthy Sleep As Per The Guidelines by The World Sleep Society March 19, 2021
Sipping Warm Water, the First Thing in the Morning is Good for DigestionMarch 18, 2021